

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 July 2002 (04.07.2002)

PCT

(10) International Publication Number  
**WO 02/051383 A2**

(51) International Patent Classification<sup>7</sup>: **A61K 9/00**

(21) International Application Number: **PCT/US01/49617**

(22) International Filing Date:  
27 December 2001 (27.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/258,369 27 December 2000 (27.12.2000) US

(71) Applicants: **GENZYME CORPORATION** [US/US];  
One Kendall Square, Cambridge, MA 02139 (US). **FO-  
CAL, INC.** [US/US]; 4 Maguire Road, Lexington, MA  
02421-3112 (US).

(72) Inventors: **PHILBROOK, Michael, C.**; 365 Marlbor-  
ough Street #6, Boston, MA 02115 (US). **BURNS, James,  
W.**; 182 Standish Road, Watertown, MA 02172 (US).  
**SKINNER, Kevin, C.**; 8 Midland Circle, Andover, MA  
01810 (US). **MILLER, Robert, J.**; 59 Fairway Drive,  
Halifax, MA 02338 (US).

(74) Agent: **BLUNDELL, Isabelle**; Genzyme Corporation,  
Legal Department, One Kendall Square, Cambridge, MA  
02139 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

**Published:**

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: **CONTROLLED RELEASE OF ANTI-ARRHYTHMIC AGENTS**

(57) Abstract: Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed *in vitro* or *in vivo*. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.

WO 02/051383 A2

## CONTROLLED RELEASE OF ANTI-ARRHYTHMIC AGENTS

### BACKGROUND OF THE INVENTION

5 The present invention is generally in the field of controlled drug delivery, and particularly in the area of direct delivery of anti-arrhythmic agents to the surface of the heart and its associated tissues.

Coronary artery bypass graft (CABG) surgery is a standard surgical that procedure that replaces clogged or degraded cardiac arteries. However, the act of operating on the heart can disturb the regulation of the heartbeat.  
10 Postsurgical arrhythmias resulting from this disturbance can complicate the recovery process and can be fatal.

Atrial fibrillation is the most common postsurgical arrhythmic event following open heart surgery. Postoperative atrial fibrillation has been found to occur following approximately 20-30% of all CABG and valve  
15 procedures, and usually occurs within 10 days following surgery. Anti-arrhythmic drugs typically are administered orally or by IV either to treat atrial fibrillation when it occurs or as a prophylactic therapy. However, systemic administration of anti-arrhythmic agents is not always desirable or practical.

20 Administration of anti-arrhythmic agents to cardiac tissue, directly or on a pacemaker lead, has been proposed in U.S. Patent No. 5,387,419 and WO 94/21237 to Levy and Sintov. U.S. Patent No. 5,387,419 describes the direct application of anti-arrhythmic agents in a carrier. However, this application has proven to be impractical because the carriers are not tissue  
25 adherent and do not bioresorb. For example, U.S. Patent Number 5,387,419 describes placing lidocaine in polyurethane, which must be prepared outside the body at 60 °C and then sutured to the heart.

There is a need for more practical methods of administration of anti-arrhythmic agents.

30 It is therefore an object of this invention to provide controlled delivery of anti-arrhythmic drugs through the direct application of tissue adherent polymeric hydrogel matrices.

## SUMMARY OF THE INVENTION

Methods for the simple, reliable application and local controlled release of selected anti-arrhythmic drugs to tissues of the heart or blood vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that adhere to the tissues to which the anti-arrhythmic drugs are to be delivered and then biodegrade. The hydrogels compositions and patches containing anti-arrhythmic drugs may be formed *in vitro* or *in vivo*. The hydrogels are particularly well suited for the delivery of poorly soluble drugs, such as amiodarone. Preferred hydrogels are tissue adherent and biodegradable within seven to ten days following application. Most preferred hydrogels are formed of synthetic polymers that provoke minimal inflammation or fibrosis. The hydrogels can be applied directly to the tissue where drug delivery is desired, by spraying or painting the gel onto the tissue, or in the form of a "patch" that provides a defined dosage of drug for release at the site of application.

As demonstrated by the examples, in a preferred embodiment, hydrogels that are formed by photopolymerization of a diacrylated polyethyleneglycol macromer containing hydrolysable linkages (FOCALSEAL™) provide effective delivery of anti-arrhythmic drugs such as amiodarone applied directly to the atrium in animal models including dogs and pigs to increase the atrial effective refractory period ("AERP"). The hydrolysable linkages are either lactide-trimethylenecarbonate oligomers or trimethylenecarbonate oligomers, that are cleaved by hydrolysis following application, degrading into simple metabolic products that are non-toxic.

## BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph of the temporal release of amiodarone from hydrogels (cumulative percent (%) of amiodarone released over time in the square root of hours). It depicts the release of amiodarone in three different particle sizes, 25  $\mu\text{m}$  ( $\blacktriangle$ ), 19  $\mu\text{m}$  ( $\blacksquare$ ), and less than 1  $\mu\text{m}$  ( $\blacklozenge$ ).

Figure 2A is a graph of modulus (kPa) and pH of FOCALSEAL-L® hydrogels formed with increasing concentrations of CORDARONE, up to

20% loading of the hydrogel. Figure 2B is a graph of modulus (kPa) and pH as a function of amiodarone loading up to 10% of the FOCALSEAL-L® hydrogel.

Figure 3 is a graph of adherence scores for FOCALSEAL-L® hydrogel patches polymerized *in vitro*, then applied to pig lung tissue, as a function of the polymerization time in seconds, up to 40 seconds.

Figure 4 is a graph of average amiodarone concentrations in porcine atrial and ventricular tissue following delivery to the tissue from 1% and 4% loaded FOCALSEAL-S® hydrogels for a period of seven days.

Figure 5A is a graph of viscosity (cp) for 7% FOCALSEAL-S™, alone or in combination with 1%, 2%, 3%, or 4% HA, and 5% FOCALSEAL-S™, alone or in combination with 5% HA.

Figure 5B is a graph of modulus (kPa) and pH of 5% FOCALSEAL-S™ in combination with 5% HA, alone or in further combination with 0.5% or 1% amiodarone, and 7% FOCALSEAL-S™ in combination with 3% HA, alone or in further combination with 0.5% or 1% amiodarone.

## DETAILED DESCRIPTION OF THE INVENTION

### I. Compositions

The compositions contain a biocompatible, polymeric hydrogel matrix that is tissue adherent and preferably degrades in a period of time minimizing tissue inflammation, for example in less than seven to ten days, and an anti-arrhythmic agent, preferably in an amount effective to lengthening the atrial effective refractory period ("AERP").

#### A. Hydrogel Matrix

To achieve the above properties, the hydrogel is formed primarily of polymerized macromers, the macromers being themselves polymers or copolymers of one or more monomers having reactive groups providing resorbable linkages and polymerizable sites for biodegradability and polymerization. The macromers have sufficient hydrophilic character to form water-absorbent polymerized gel structures, and are at least dispersible in a substantially aqueous solution, and preferably are water-soluble, to maximize tissue adherence. The macromers are preferably made

predominantly of synthetic materials. The resulting hydrogels are preferably highly compliant, so as not to impede the process of cardiac contraction. The hydrogels are preferably covalently crosslinked to ensure that they are retained at the site of application until the hydrogels degrade.

5                    *Monomer and Macromer Components of the Hydrogel*

Monomers and macromers which are suitable for forming the hydrogels ("referred to here in this section collectively as "monomers") have one or more of the following properties: water soluble, partially macromeric character, containing hydrophilic groups, and being covalently reactive.

- 10    When crosslinked to form gels, the resulting gels are tissue adhesive, elastic, and compliant. The monomers are preferably water soluble. Water soluble materials are soluble to at least about 0.1 gram per liter of a substantially aqueous solvent. A substantially aqueous solvent comprises at least about 50% by weight of water, and less than about 50% by weight of a non-  
15    aqueous, water-miscible solvent. If the polymers are not entirely water soluble, they should be dispersible in water, and form micelles, typically with the aid of non-aqueous, water-miscible solvents. The non-aqueous solvent must be present in an amount that does not damage the tissue. Thus only a small amount of non-aqueous, water-miscible solvent should be  
20    present in the pre-gelled composition to minimize tissue irritation. Up to about 10% by weight of the solution can be a non-aqueous, water-miscible solvent. Examples of non-aqueous, water-miscible solvents include ethanol, isopropanol, *N*-methylpyrrolidone, propylene glycol, glycerol, low molecular weight polyethylene glyco, DMSO, Benzyl alcohol, and benzylbenzoate.  
25    Liquid surfactants, such as poloxamers (e.g., PLURONIC™ surfactants) and some polyethylene glycol derivatives (e.g., some TWEEN™ surfactants) can also be used as non-aqueous, water-miscible solvents.

- 30    The monomers are preferably at least partially macromeric, and are more preferably substantially to completely macromeric. Macromers tend to be innocuous to tissue because they will not readily diffuse into or penetrate cells. A macromer is a reactive monomer consisting of a polymeric material with a number-average or weight-average molecular weight of about 500

Daltons or more and at least one reactive group. To form a crosslinked gel by chain-growth polymerization, the macromers, along with any other smaller monomers, in a solution must contain on average more than one reactive group (which may be a covalently reactive group, or a group that binds non-covalently to other macromers). For polymerizations involving step-growth polymerization, the macromers must contain on average more than two reactive groups, and the solution typically contain approximately equal numbers of the two different types of reactive groups. An example of step-growth polymerization is gelation by formation of urethane linkages from the reaction of isocyanate with the hydroxyl groups. For free-radical polymerization of unsaturated materials (chain-growth polymerization), the monomers must contain on average more than one reactive group to crosslink.

The macromers have significant hydrophilic character so as to form water-absorbent gel structures. At least some of the macromers, and preferably most of the macromers, contain hydrophilic domains. A hydrophilic domain in a macromer is a hydrophilic group, block, or region of the macromer that would be water soluble if prepared as an independent molecule rather than being incorporated into the macromer. Hydrophilic groups are required for water dispersibility or solubility, and for retention of water by the gel after gelation, or upon rehydration after drying. The hydrophilic groups of the macromers are preferably made predominantly or entirely of synthetic materials. Synthetic materials of controlled composition and linkages are typically preferred over natural materials due to more consistent degradation and release properties.

Examples of useful synthetic materials include those prepared from poly(ethylene oxide), partially or fully hydrolyzed poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethylloxazoline), poly(ethylene oxide)-co-poly(propylene oxide) block copolymers (poloxamers and merioxapols), and poloxamines. Preferably, the water-soluble polymeric blocks are made from poly(ethylene oxide). Preferably, at least 50% of the macromers is formed of synthetic materials.

The hydrophilic groups of the macromers may also be derived from natural materials. Useful natural and modified natural materials include carboxymethyl cellulose, hydroxyalkylated celluloses such as hydroxyethyl cellulose and methylhydroxypropyl cellulose, polypeptides, polynucleotides, polysaccharides or carbohydrates such as Ficoll™ polysucrose, hyaluronic acid and its derivatives, dextran, heparan sulfate, chondroitin sulfate, heparin, or alginate, and proteins such as gelatin, collagen, albumin, or ovalbumin. Preferably the percentage of natural material does not exceed about 50% percent.

The monomers are preferably covalently reactive, and thus form a covalently crosslinked gel. The crosslinked gels are elastic, and further are both elastic and compliant with soft tissue at low polymer concentrations.

Any method of covalent polymerization is potentially useful in the formation of the gels. The reactive groups may include, without limitation, ethylenically unsaturated groups, isocyanates, hydroxyls and other urethane-forming groups, epoxides or oxiranes, sulfhydryls, succinimides, maleimides, amines, thiols, carboxylic acids and activated carboxyl groups, sulfonic acids and phosphate groups. Ethylenically unsaturated groups include acrylates and other unsaturated carboxylic acids, vinylic and allylic groups, cinnamates, and styrenes. Activated carboxyl groups include anhydrides, carbonylimidazoles, succinimides, carbonyl nitrophenols, thioesters, O-acyl ureas, and other conjugated carbonyls. In general, any reactive group that will covalently bond to a second and that can maintain fluidity when exposed to water for enough time to allow deposition and reaction is of use in making a suitable reactive macromer. Due to their excellent stability and slow reactivity in aqueous solutions, ethylenically unsaturated reactive groups are preferred.

The polymerization reaction does not have to result in covalent bonds. A number of materials are known which can form gel structures by changing the ionic conditions of the medium (e.g. alginate) or by changing the temperature of the medium (e.g., agarose, certain poloxamers). Polysaccharides are typical of these materials. Gel-like structures can be

formed from proteins, such as gelatin or fibrin. While it may be more difficult to get these materials to adhere strongly to tissue, they are potentially of use in the hydrogels, particularly as depots for the drug.

5       Gel formation can be accelerated by inclusion of small (non-macromeric) polymerizable molecules that can assist in linking larger, polymeric macromers. These typically have molecular weights less than about 100 Da, more preferably less than 500 Da. For free radical polymerization, any of the common ethylenically unsaturated molecules can be used. These include derivatives of acrylic and methacrylic acid, such as  
10       acrylamide, hydroxyethyl methacrylate (HEMA), and diacrylated or polyacrylated glycols and oligoglycols. Allyl groups (e.g., allyl glycidyl ether) and vinyl groups (e.g., N-vinyl caprolactam and N-vinyl pyrrolidone) are also of use. Other unsaturated compounds include cinnamic acid and its esters, and maleic, fumaric and itaconic acids and their derivatives.

15       Similar small molecules can be used to accelerate electrophilic/nucleophilic reactions, such as small polyamines, polyols and polythiols, polyisocyanates, and polysuccinimides.

      In the preferred embodiment, the gel is a "FOCALGEL<sup>TM</sup>", i.e., a biodegradable, polymerizable macromer having a solubility of at least about  
20       1 g/100 ml in an aqueous solution comprising at least one water soluble region, at least one degradable region which is hydrolyzable under *in vivo* conditions, and free radical polymerizable end groups having the capacity to form additional covalent bonds resulting in macromer interlinking, wherein the polymerizable end groups are separated from each other by at least one  
25       degradable region, as described in U.S. Patent No. 5,410,016, incorporated herein by reference in its entirety. The individual polymeric blocks can be arranged to form different types of block copolymers, including di-block, tri-block, and multi-block copolymers. The most preferred embodiment is a di-block copolymer including a water-soluble block linked to a biodegradable  
30       block, with both ends capped with a polymerizable group, where the biodegradable blocks are a carbonate or hydroxyacid monomer such as a lactide monomer or oligomer.



The biodegradable region is preferably hydrolyzable under *in vivo* conditions. For example, hydrolyzable group may be polymers and oligomers of glycolide, lactide,  $\epsilon$ -caprolactone, other  $\alpha$ -hydroxy acids, and other biologically degradable polymers that yield materials that are non-toxic or present as normal metabolites in the body. Preferred poly( $\alpha$ -hydroxy acid)s are poly(glycolic acid), poly(DL-lactic acid) and poly(L-lactic acid). Other useful materials include poly(amino acids), poly(anhydrides), poly(orthoesters), and poly(phosphoesters). Polylactones such as poly( $\epsilon$ -caprolactone), poly( $\epsilon$ -caprolactone), poly( $\delta$ -valerolactone) and poly(gamma-butyrolactone), for example, are also useful.

As used herein, a carbonate is a functional group with the structure --O--C(O)--O--. The carbonate starting material can be cyclic, such as trimethylene carbonate (TMC), or can be linear, such as dimethylcarbonate (CH<sub>3</sub> O--C(O)--OCH<sub>3</sub>). After incorporation into the polymerizable macromer, the carbonate will be present at least in part as R--O--C(O)--O--R', where R and R' are other components of the macromer. More preferred carbonates are the cyclic carbonates, which can react with hydroxy-terminated polymers without release of water. Suitable cyclic carbonates include ethylene carbonate (1,3-dioxolan-2-one), propylene carbonate (4-methyl-1,3-dioxolan-2-one), trimethylene carbonate (1,3-dioxan-2-one) and tetramethylene carbonate (1,3-dioxepan-2-one).

In the most preferred embodiments, the macromers contain between about 0.3% and 20% by weight of carbonate residues, more preferably, between about 0.5% and 15% carbonate residues, and most preferably, about 1% to 5% carbonate residues. In those embodiments where hydroxy acid residues are desired, the macromer contains between about 0.1 and 10 residues per residue of carbonate, more preferably between about 0.2 and 5, and most preferably one or more such residue per macromer. In this preferred embodiment, the macromer includes a core of a hydrophilic poly(ethyleneoxide) oligomer (a.k.a. poly(ethyleneglycol) or PEG) with a molecular weight between about 400 and 40,000 Da, most preferably 25,000 Da; an extension on both ends of the core which includes 1 to 10 carbonate

residues and optionally between one and five hydroxyacid residues, preferably alpha-hydroxy acid residues, most preferably lactic acid residues, with a molecular weight of about 50 to 300 Da; wherein the total of all residues in the extensions is sufficiently small to preserve water-solubility of the macromer, being typically less than about 20% of the weight of the macromer, more preferably 10% or less. The ends are capped with ethylenically-unsaturated (i.e., containing carbon-carbon double bonds) caps, with a preferred molecular weight between about 50 and 300 Da, most preferably acrylate groups having a molecular weight of 55 Da. These materials are described in U.S. Patent No. 6,177,095 to Sawhney, et al. (incorporated herein by reference in its entirety). See also U.S. Patent No. 5,900,245 to Sawhney, et al. (incorporated herein by reference in its entirety).

The macromers can be synthesized using means well known to those of skill in the art. General synthetic methods are found in the literature, for example in U.S. Patent No. 5,410,016 to Hubbell et al., U.S. Patent No. 4,243,775 to Rosensaft et al., and U.S. Patent No. 4,526,938 to Churchill et al. (incorporated herein by reference in their entirety). For example, a polyethylene glycol backbone can be reacted with trimethylene carbonate (TMC) or a similar carbonate in the presence of a Lewis acid catalyst, such as stannous octoate, to form a TMC-polyethylene glycol terpolymer. The TMC-PEG polymer may optionally be further derivatized with additional degradable groups, such as lactate groups. The terminal hydroxyl groups can then be reacted with acryloyl chloride in the presence of a tertiary amine to end-cap the polymer with acrylate end-groups. Similar coupling chemistry can be employed for macromers containing other water-soluble blocks, biodegradable blocks, and polymerizable groups, particularly those containing hydroxyl groups.

When polyethylene glycol is reacted with TMC and a hydroxy acid in the presence of an acidic catalyst, the reaction can be either simultaneous or sequential. The simultaneous reaction will produce an at least partially random copolymer of the three components. Sequential addition of a

hydroxy acid after reaction of the PEG with the TMC will tend to produce an inner copolymer of TMC and one or more PEGs, which will statistically contain more than one PEG residue linked by linkages derived from TMC, with hydroxy acid largely at the ends of the (TMC, PEG) region. When the  
5 hydroxy acid contains a secondary hydroxyl, as in lactic acid, then the tendency towards rearrangement is reduced.

Upon reaction of, for example, trimethylene carbonate (TMC) with polyethylene glycol (PEG), the TMC linkages in the resulting copolymers have been shown to form end linked species of PEG, resulting in segmented  
10 copolymers, i.e. PEG units coupled by one or more adjacent TMC linkages. The length of the TMC segments can vary. Coupling may also be accomplished via the carbonate subunit of TMC. These segmented PEG/TMC copolymers form as a result of transesterification reactions involving the carbonate linkages of the TMC segments during the TMC  
15 polymerization process when a PEG diol is used as an initiator. If the product of this first reaction step is then reacted with a reactive end-capping material, such as acryloyl chloride, a significant percentage of the macromer end groups can be PEG hydroxyls, resulting in the attachment of the reactive groups directly to one end of a non-biodegradable PEG molecule. Such a  
20 reaction of the PEG/TMC segmented copolymers can be prevented by adding additional segments of other hydrolyzable co-monomers (e.g. lactate, glycolate, 1,4-dioxanone, dioxepanone, caprolactone) on either end of the PEG/TMC segmented copolymer. The basic PEG/TMC segmented copolymer or the further reacted PEG/TMC/comonomer segmented  
25 terpolymer is then further reacted to form crosslinkable macromers by affixing reactive end groups (such as acrylates) to provide a macromer with reactive functionality. Subsequent reaction of the end groups in an aqueous environment results in a bioabsorbable hydrogel.

Polymerization is initiated by any convenient reaction, including  
30 photopolymerization, chemical or thermal free-radical polymerization, redox reactions, cationic polymerization, and chemical reaction of active groups (such as isocyanates, for example.) Polymerization is preferably initiated

using photoinitiators. Photoinitiators that generate a free radical or a cation on exposure to UV light are well known to those of skill in the art. Free-radicals can also be formed in a relatively mild manner from photon absorption of certain dyes and chemical compounds. The polymerizable groups are preferably polymerizable by free radical polymerization. The preferred polymerizable groups are acrylates, diacrylates, oligoacrylates, methacrylates, dimethacrylates, oligomethacrylates, cinnamates, dicinnamates, oligocinnamates, and other biologically acceptable photopolymerizable groups.

These groups can be polymerized using photoinitiators that generate free radicals upon exposure to light, including UV (ultraviolet) and IR (infrared) light, preferably long-wavelength ultraviolet light (LWUV) or visible light. LWUV and visible light are preferred because they cause less damage to tissue and other biological materials than short-wave UV light. Useful photoinitiators are those which can be used to initiate polymerization of the macromers without cytotoxicity and within a short time frame, minutes at most and most preferably seconds. Exposure of dyes, preferably in combination with co-catalysts such as amine, to light, preferably visible or LWUV light, can generate free radicals. Light absorption by the dye causes the dye to assume a triplet state, and the triplet state subsequently reacts with the amine to form a free radical which initiates polymerization, either directly or via a suitable electron transfer reagent or co-catalyst, such as an amine. Polymerization can be initiated by irradiation with light at a wavelength of between about 200-1200 nm, most preferably in the long wavelength ultraviolet range or visible range, 320 nm or higher, and most preferably between about 365 and 550 nm.

Numerous dyes can be used for photopolymerization. Suitable dyes are well known to those of skill in the art. Preferred dyes include erythrosin, phloxime, rose bengal, thionine, camphorquinone, ethyl eosin, eosin, methylene blue, riboflavin, 2,2-dimethyl-2-phenylacetophenone, 2-methoxy-2-phenylacetophenone, 2,2-dimethoxy-2-phenyl acetophenone, other acetophenone derivatives, and camphorquinone. Suitable cocatalysts include

amines such as N-methyl diethanolamine, N,N-dimethyl benzylamine, triethanol amine, triethylamine, dibenzyl amine, N-benzylethanolamine, N-isopropyl benzylamine. Triethanolamine is a preferred cocatalyst.

- 5 Suitable chemical, thermal and redox systems may initiate the polymerization of unsaturated groups by generation of free radicals in the initiator molecules, followed by transfer of these free radicals to the unsaturated groups to initiate a chain reaction. Peroxides and other peroxygen compounds are well known in this regard, and may be considered as chemical or thermal initiators. Azobisbutyronitrile is a chemical initiator.
- 10 A combination of a transition metal, especially iron, with a peroxygen and preferably a stabilizing agent such as glucuronic acid allows generation of free radicals to initiate polymerization by a cycling redox reaction.

- It is also possible to use the macromers with other types of linking reactions. For example, a macromer could be constructed with amine termination, with the amine considered as an active group; and another macromer could be constructed with isocyanate termination, with the isocyanate as the active group. On mixing, the materials will spontaneously react to form a gel. Alternatively, an isocyanate-terminated macromer could be polymerized and crosslinked with a mixture of diamines and triamines.
- 15
- 20 Other pairs of reactants include maleimides with amines or sulfhydryls, or oxiranes with amines, sulfhydryls or hydroxyls.

- The copolymers and macromers can have tailorable solubility and solution viscosity properties. The hydrogels can have tailorable modulus and degradation rate. For a given solution concentration in water, the viscosity is affected by the degree of end linking, the length of the TMC (and other hydrophobic species) segments, and the molecular weight of the starting PEG. The modulus of the hydrogel is affected by the molecular weight between crosslinks. The hydrogel degradation rate can be modified by adding a second, more easily hydrolyzed comonomer (e.g. lactate, glycolate, 1,4-dioxanone) as a segment on the ends of the basic PAG/TMC copolymer prior to adding the crosslinkable end group to form the macromer.
- 25
- 30

In some cases it is desirable to increase the viscosity of the macromer solution at the time of application to the tissue so that the macromer remains more firmly at the site of application. Polymers which can be used to increase the viscosity of the macromer solution include: glycosaminoglycans (GAG) such as hyaluronic acid (HA), carboxymethyl cellulose (CMC), dextran, dextran sulfate, and polyvinylpyrrolidone (PVP). These are typically added to the macromer solution immediately before application to the tissue.

As used herein, a "biodegradable" material is one that decomposes under normal *in vivo* physiological conditions into components that can be metabolized or excreted. Functional groups having degradable or resorbable linkages are incorporated into the structure of the hydrogel matrix to provide for its resorption over time. These functional groups may be incorporated within the macromers to form part of the backbone of the polymer strands of the hydrogel or as crosslinks between the polymer strands. Examples of degradable units may include, but are not limited to, esters, carbonates, carbamates and the like.

The length of time it takes for the hydrogel to biodegrade may be tailored to provide a hydrogel that persists long enough to generate the required tissue level of the drug through the critical period, which extends from about the second postoperative day to about the seventh postoperative day, or preferably from about the first or second postoperative day to about the tenth or fourteenth. Given the achievement of this objective, shorter degradation or resorption times such as less than about three months are generally preferred. Degradation or resorption times less than about fifteen days are particularly preferred.

As used herein, a "biocompatible" material is one that stimulates only a mild, often transient, implantation response, as opposed to a severe or escalating response. Biocompatibility may be determined by histological examination of the implant site at various times after implantation. One sign of poor biocompatibility can be a severe, chronic, unresolved phagocytic response at the site. Another sign of poor biocompatibility can be necrosis or

regression of tissue at the site. In the preferred embodiment, a biocompatible material elicits a minimal or no fibrosis or inflammation. This can be achieved through selection of hydrogel composition, and particularly through the use of hydrogel components resulting in degradation of the hydrogel *in vivo* in less than about two weeks, more preferably within seven to ten days.

A material is tissue adherent if it requires a force to remove the material from the tissue. Thus, the general and practically useful measurement of adherence is that the gel, when applied to the tissue, remains attached to the tissue for at least as long as is required to obtain the therapeutic effect of the drug. Typically, this time period will be sufficiently long to observe at least about 10% elution of the drug, and preferably 20% elution or more, before detachment or degradation of the gel.

*Ex vivo* tests can be used to determine a material's potential adherence. In evaluating potential adherence of materials, it is useful to have an *in vitro* test to determine formulations that are likely to have the desired degree of adherence to the tissue surface. One method of judging adherence is to require that upon a gradual increase in a detaching force, the force required to remove the gel from the tissue is greater than or approximately equal to the force required to cause cohesive failure of the gel (or the tissue, if lesser). Thus on attempting to remove the material, either the material or the tissue experiences cohesive failure at a lesser force than, or at approximately the same force as, the force at which the bond between the material and the tissue experiences adhesive failure. Materials that require a force of about 20 dynes/cm<sup>2</sup> to remove them from the tissue are sufficiently adhesive for delivery of anti-arrhythmic agents.

Adherence can be described qualitatively as "excellent", when cohesive failure is required for removal from the surface, "good" when failure is partially cohesive and partially adhesive, "fair" when removal requires only adhesive failure (i.e., detachment of the gel from the surface) and more than 20 dynes/cm<sup>2</sup> of force is required to produce adhesive failure, and "poor" if none of these criteria are satisfied. Force can be measured

using a mechanical properties tester, such as an Instron™ tester or other device.

*In vitro* adherence that is “good”, “excellent”, or, in many cases, “fair”, has generally been observed to be sufficient for *in vivo* use. However, these *in vitro* measurements are for convenience, and the formulation may need to be optimized based on *in vivo* release of drug before detachment.

The hydrogels are preferably highly compliant with the tissue to which they adhere. Thus, the gels stretch and bend along with the tissue. Cardiac tissue is in continual motion, and the hydrogel should not significantly disturb this motion. It is preferable that the response to stress within these limits be substantially elastic, i.e., reversible. Thus the hydrogel should remain as a coherent material for at least the period required for delivery of the anti-arrhythmic agent.

In a preferred embodiment, the hydrogel composition is selected to provide acceptable levels of fibrosis or tissue reaction. This can be achieved through the selection of the reactive formulation, and other techniques known to those skilled in the art in drug delivery utilizing polymeric delivery devices.

#### B. Anti-arrhythmic Agents

Anti-arrhythmic agents are used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. A modification of the classification system proposed by Vaughan-Williams is a frequently used classification system for anti-arrhythmic agents. This classification system is based in part on the ability of anti-arrhythmic agents to modify the cardiac cellular excitatory currents ( $\text{Na}^+$  or  $\text{Ca}^{2+}$ ), action potential duration and automaticity. These effects of the agents on isolated cardiac cells are believed to be responsible for some of the anti-arrhythmic properties of the agents. (See Harrison's Principles of Internal Medicine (13<sup>th</sup> Ed.), p. 1032-1034 (McGraw-Hill Inc. 1994) for additional information.)



Anti-arrhythmia agents are often organized into four main groups according to their mechanism of action: type I, sodium channel blockade; type II, beta-adrenergic blockade; type III, repolarization prolongation; and type IV, calcium channel blockade. Type I anti-arrhythmic agents include lidocaine, moricizine, mexiletine, tocainide, procainamide, encainide, flecanide, tocainide, phenytoin, propafenone, quinidine, disopyramide, and flecainide. Type II anti-arrhythmic agents include propranolol and esmolol. Type III includes agents that act by prolonging the duration of the action potential, such as amiodarone, artilide, bretylium, clofilium, isobutilide, sotalol, azimilide, dofetilide, dronedarone, ersentilide, ibutilide, tedisamil, and trecetilide. Type IV anti-arrhythmic agents include verapamil, diltiazem, digitalis, adenosine, nickel chloride, and magnesium ions.

The preferred anti-arrhythmic agents are poorly soluble in water (i.e. hydrophobic). In terms of the solubility classification of the United States Pharmacopoeia (USP 24/NF 19, effective January 1, 2000; p. 2254), the preferred solubility classes are: "slightly soluble", requiring 100 to 1000 parts of solvent to dissolve; "very slightly soluble", requiring 1000 to 10,000 parts of solvent; and "practically insoluble, or insoluble", requiring over 10,000 parts of solvent. Collectively, these classes are defined herein as "poorly soluble". Of the various classes of anti-arrhythmic agents, type III are preferred. Of these, amiodarone, dronedarone and sotalol are preferred, and amiodarone is the most preferred anti-arrhythmic agent for delivery in a hydrogel. Dronedarone is similar to amiodarone and is believed to be at least as insoluble in water.

Amiodarone hydrochloride (amiodarone) is an approved class III anti-arrhythmic drug. Amiodarone is a potassium channel blocker that prolongs the action potential duration and refractory period of all cardiac fibers. (See *Dorland's Illustrated Medical Dictionary* 28<sup>th</sup> ed. (W.B. Saunders Co. 1994)) Amiodarone is typically administered orally in multiple doses over an extended period of time to reduce the risk of atrial fibrillation. It has a reduced clearance rate and a very long half-life, and is associated with numerous side effects at the conventional therapeutic dose.

Amiodarone applied in a single application directly to the heart is expected to be similarly effective, with a potential reduction in side effects because a lower required dose is anticipated.

C. Formulations

5           The slow dissolution rate for poorly soluble anti-arrhythmic agents controls their rate of efflux from the gel. The rate of efflux for such anti-arrhythmic agents can also be controlled by selecting the particle size of the drug particles that are suspended in the macromer solution before its polymerization. Particles of a particular size can be made by any known  
10   method, including grinding, milling, cryofracture, precipitation, spraying, spray drying, and/or classification. Dispersion and stabilization of the particles within the macromer solution may be achieved with the use of surfactants such as, but not limited to, PLURONIC.

          It has been discovered, as demonstrated in Example 3, that a  
15   precipitated nanoparticle form is the preferred formulation for amiodarone. This fine precipitate can be readily and reproducibly achieved by dilution of a stable aqueous solution of amiodarone with an aqueous solution of synthetic hydrogel-forming polymers. Surfactants and alcohols are used to make amiodarone soluble in the aqueous solution.

20           In the amphiphilic macromers used in the Examples, the hydrophobic groups form micelles in aqueous solution. These micelles may act as nucleation sites during the precipitation of amiodarone and then serve to prevent coalescence of the precipitate. If this is correct, the particle size of the drug can be controlled by varying the concentration of nucleation sites.  
25   Fewer nucleation sites per unit volume would lead to fewer but larger particles, which could slow the rate of delivery of the anti-arrhythmic agent.

          More soluble anti-arrhythmic agents can also be used, but their efflux rate from the gel usually must be altered to achieve the necessary delivery rate. Such soluble anti-arrhythmic agents include those falling in United  
30   States Pharmacopoeia classes "very soluble", "freely soluble", "soluble", and "sparingly soluble". Typical means of altering release rates include encapsulating the agents in micro particles or liposomes and conjugating the

agents to macromolecules. They can be made less soluble by altering the salt or using the free acid/base form of the agents.

Pre-encapsulation is used for the small, water-soluble drugs (typically of molecular weights less than 1000 Da) that are incorporated into hydrogels, to decrease the rate of release of these drugs. The encapsulation may be by any conventional means. One means is entrapment in micro particles of a degradable, water-insoluble polymer. Typical materials are polymers and copolymers of lactic acid, glycolic acid, and copolymers thereof (e.g., PLGA). Other materials used to form suitable micro particles are copolymers of ethylene and vinyl acetate (EVAC) and polymers of anhydrides, such as poly sebacic anhydride. Particles of drug may also be pre-encapsulated with polymers such as EVAC and PLGA, or with thin layers of materials that dissolve *in vivo*, for example, the enteric coatings or other coatings typically used for oral delivery, such as gelatin.

Release of more soluble anti-arrhythmic agents can be slowed by conjugating small molecules to polymers by degradable or reversible linkages. Many such systems are described in the art. In one embodiment, such systems are generated by immobilizing a binding or targeting molecule for the drug, such as an antibody or lectin, which is saturated with the drug, in the gel. In another typical embodiment, drug is attached to a polymer bearing reactive groups, such as to the hydroxyl of polyvinyl alcohol, to a carboxyl, sulfonate or amine group of a polysaccharide or the hydroxyl or carboxyl of an alpha-hydroxy acid (e.g., lactic or glycolic acid), or to a carboxylic group on a polymer (e.g., alginate, polyacrylic acid) via an anhydride, an ester, a carbonate, or carbamate linkage. Many similar methods are described in the art.

The solubility of some drugs, particularly amines, can be decreased by preparing them in their neutral ("free base") form. Such drugs often can also be administered as suspensions in oil, which in turn is dispersed in water, usually with surfactant stabilizers.

#### D. Levels of Drug Loading

The level of loading of the drug in the gel-forming solution will normally be as high as practical, while leaving a margin of loading to prevent premature precipitation or aggregation, or inhibition of gel formation. The level obtainable will depend on the drug; on the type of encapsulant, if present; and on the properties of the gel. The macromer solution is preferably between 3 and 20% by weight FOCALSEAL™, with 5 to 7% being most preferred. The amiodarone concentration used in the examples is typically between 0.5 and 1% by weight, but this will depend in part upon the source and form of the amiodarone. Gel polymerization rate and final gel may be significantly affected by drug concentration. Use of other macromers affects the optimal level. Fortunately, acceptable loading ranges are easily determined for a particular system by varying the loading and determining the properties of the formed gel.

#### II. Methods of Forming the Hydrogels

It is important to provide a way for the physician to deliver a well-defined amount of the AAR, so that the therapeutic effect can be obtained. In one method, the anti-arrhythmic agent is provided in a formulation that forms a hydrogel *in vivo*. In a second method, the anti-arrhythmic agent is provided to the patient in a preformed hydrogel "patch".

As noted above, the gels are formed by a polymerization reaction, which may be any reaction that can be carried out in a substantially aqueous environment and is not damaging to tissue. The gels may be polymerized *in vivo* or *in vitro*.

As discussed above, adherence of gels to tissue can be optimized by techniques that employ functional primers, as described in U.S. Patent Nos. 5,800,373 to Melanson et al., 5,844,016, or 5,900,245 to Sawhney et al. for gels formed by polymerization of ethylenically unsaturated precursors. Suitable gel compositions form strong bonds to tissue. These techniques are also applicable to creating strong adherence of the materials to tissue, including tissue to which it is difficult to obtain adherence by conventional methods, for example, cartilage.

A general procedure for applying materials to the tissue involves brushing or dabbing primer over a larger area than that over which the material is applied. Thereafter, material is brushed or dabbed over the deposited primer. Then bulk material is applied by dripping (if liquid) or spreading (if paste) over yet a smaller area of the treated zone. Then light (at appropriate wavelength, intensity, distance and for an appropriate time) is applied at each zone, or other means of polymerizing the material are used.

A. *In Vivo Polymerization*

In this embodiment, the drug is formulated in appropriate excipients (if any) in a vial, and is taken up in a known amount of hydrogel forming material. This solution is applied to the tissue, and polymerization is effected to form a gel adherent to the tissue.

In the preferred embodiment, the solution is polymerized by illumination of a photoinitiator or photosensitizer in the solution. In this case, the mixing of two solutions at the time of application will not necessarily form a gel; however once the solutions are illuminated by light of an appropriate frequency, a gel will form, as described in U.S. Patent No. 5,410,016 to Hubbell et al. incorporated herein by reference in its entirety.

*In vivo* polymerization has the advantage of being able to produce “good” to “excellent” adherence when polymerized on the tissue surface (as defined in Table 1). This is particularly true when the tissue is first primed or otherwise pretreated with an agent (primer) stimulating polymerization (as known to those skilled in the art, for example, as described in U.S. Patent Nos. 5,844,016 to Sawhney et al. and 5,834,274 to Hubbell et al. incorporated herein by reference in their entirety) prior to the application of the macromer composition containing the anti-arrhythmic drug. See also U.S. Patent Nos. 5,567,435; 5,844,016; 5,986,043; 6,060,582; and 6,306,922 incorporated herein by reference in their entirety. In these methods, an aqueous solution containing a photoinitiation system, including one or more photoinitiators, photosensitizers and co-initiators, amine or amide electron transfer agent, redox accelerant system for the photoinitiation system (such as a metal ion and a peroxide); and a photopolymerizable macromer solution,

are applied to the tissue, and the solution is polymerized by exposure to UV or visible light at room or body temperature.

B. In Vitro Polymerization

In a second embodiment, hydrogel patches containing anti-  
5 arrhythmic drugs are polymerized *in vitro* and then adhered to the tissue surface. The drug in any of the above formulations can be entrapped in a hydrogel *in vitro*, which is optionally preserved by freezing or drying, and is subsequently transferred to the cardiac tissue. The preformed gel patch, or more than one preformed gel patch, is then adhered to the cardiac tissue.  
10 Adhesion of the patch may be achieved by the polymerization of a hydrogel-forming material, which may be the same as or different from the material used to form the gel patch, placed between the preformed gel patch and the tissue, or optionally encapsulates the entire pre-formed gel. Adhesion may also be achieved by completing polymerization of a partially polymerized gel  
15 patch onto the tissue. A partially polymerized gel patch is prepared by reducing time exposure to polymerization conditions or by quenching polymerization.

*In vitro* polymerization has the advantage of providing a reliable means of delivering a precisely defined dose of the drug. The preformed  
20 gels should have the same properties as gels formed *in vivo*.

This method of application may be regarded as another form of application of an encapsulated drug to the tissue, since the adhesion to the tissue is provided by a hydrogel that is formed *in situ* on the tissue. The preferred method of attaching the gels to the tissue surface is to use  
25 macromer solutions to adhere the preformed gel to the tissue. Adherence is also preferably in the "good" to "excellent" range (see Table 1).

Techniques for producing strong adherence of the gel to the tissue include applying an initiator or promoter of polymerization to the tissue at the site; applying a thin layer of gelling solution having a high concentration  
30 of a polymerizable reagent at the site; applying materials bearing one half of a reactive pair to the site, optionally a member of a reactive pair which is also reactive with tissue; and applying mechanical action to a layer of

polymerizable material on the tissue (before polymerization) to ensure that no layer of fluid, such as mucus or the like, separates the polymerizable material from the tissue.

### III. Methods of Using the Hydrogels

5           Any medical treatment that exposes or disturbs the heart has the potential to stimulate arrhythmias. Open heart operations are prominent among these treatments, including particularly cardiac bypass surgery and valve replacement. Other treatments that may benefit from application of anti-arrhythmic agents include implantation of pacemakers and pacemaker  
10       leads, cardiac reduction surgery, aneurysm repair, and angioplasty, stenting, and other endovascular treatments for coronary obstruction.

          The conventional mode of administration of anti-arrhythmic agents is oral or intravascular, resulting in systemic delivery. Typically, in systemic  
15       delivery, a larger initial dose is given, and then a smaller maintenance level is continued for several days or up to a week. Some studies indicate that the period of highest risk of arrhythmia is about four to seven days after surgery. Kinetics of build-up in the cardiac tissue are complex, in part because of the poor solubility of some anti-arrhythmic drugs and their accumulation into fatty tissue, such as amiodarone.

20           However, as described herein, the gel can be applied at the time of surgery and the drug delivered directly to the affected cardiac tissue. This simplifies the kinetics of penetration of the drug into the tissue. When polymerized *in situ*, the gel can be applied in open surgery by any method. In endoscopic surgery, it is preferably brushed or sprayed onto the tissue  
25       surface using a device designed for percutaneous use, but may be dripped from a mixing apparatus. When used to treat the inside of vessels, catheters such as those described in U.S. Patent No. 5,947,977 to Slepian et al. or U.S. Patent No. 5,779,673 to Roth et al. can be used to apply the gel.

          The dosage of anti-arrhythmic drugs for use in a human or animal  
30       and its minimum duration can be determined with only routine experimentation in view of the animal studies presented in the examples below and the known drug kinetics, including half-life, solubility and other

readily ascertainable properties. The effective dosage can be determined from tissue concentrations and physiological effects over time in cardiac tissue of animals, after application of a known concentration of the drug in the hydrogel. For example, it has been found that administration of about 1.5 mg of amiodarone to rabbit heart, in essentially the formulation described in Example 1 below, produced a tissue loading at seven days of about 20 to 40 micrograms per gram of tissue, which is believed to be in the therapeutic range. Such animal studies are routine in determining dosage for any drug. The dosage of the drug will also be optimized based on the period of time over which delivery is to be obtained and the release rate from the hydrogel as well as the degradation characteristics of the hydrogel, to deliver a dosage effective to lengthen the atrial effective refractory period (AERP) in the heart tissue.

#### *Amiodarone*

In the particular case of amiodarone, its insolubility means that it is relatively slow to equilibrate in the cardiac tissue and relatively slow to diffuse out once administration is discontinued. Because of these considerations, the duration of delivery of amiodarone should be at least one day. Delivery beyond about two weeks is unlikely to significantly improve the therapeutic outcome. A preferred delivery period is over a postoperative period ranging from about two days to about fourteen days, and more preferably from about four days to about seven days.

Delivery over shorter or longer periods is acceptable provided that the tissue level of amiodarone is maintained at a physiologically effective level for at least about two or three days postoperatively and preferably extending through at least seven days and more preferably at least ten days. An effective tissue level of amiodarone is preferably achieved within about one day post-operatively, or within at most two or three days.

The present invention will be further understood by reference to the following non-limiting examples.



**The following materials are used in the examples:**

PEG-based reactive macromers were used in all of the studies. These materials are available from Genzyme Biosurgery, One Kendall Square, Cambridge, MA 02139, under the trademark "FOCALSEAL<sup>TM</sup>". There are  
5 three forms: FOCALSEAL<sup>TM</sup>-S, FOCALSEAL<sup>TM</sup>-L, and FOCALSEAL<sup>TM</sup>-M. All consist of a core of PEG, partially concatenated with monomers which are linked by hydrolyzable (biodegradable) linkages, and capped at each end with a photopolymerizable acrylate group. These differ based on the molecular weight of the core PEG, the number of PEG molecules, and  
10 the number and composition of the biodegradable monomers. FOCALSEAL<sup>TM</sup>-S includes PEG with molecular weight  $19,400 \pm 4000$  Daltons; FOCALSEAL<sup>TM</sup>-L and FOCALSEAL<sup>TM</sup>-M include PEG with molecular weight  $35,000 \pm 5000$  Daltons. FOCALSEAL<sup>TM</sup>-S includes trimethylene carbonate ("TMC") monomers in a ratio of at least six or seven  
15 TMC molecules to each PEG, typically twelve to thirteen TMC molecules to each PEG, and lactide monomers, typically four lactide molecules to each PEG molecule, with a maximum of five lactide monomers to each PEG. FOCALSEAL<sup>TM</sup>-M is the same as FOCALSEAL<sup>TM</sup>-S with the exception of the molecular weight of the PEG. FOCALSEAL<sup>TM</sup>-L includes TMC  
20 molecules in a ratio of less than ten, more typically seven, TMC molecules to each PEG. U.S. Patent No. 6,083,524 describes the synthesis in detail of these materials.

These materials are polymerized by preparing a solution containing a photoinitiator system. For example, a 10 g aqueous formulation consists of 1  
25 g FOCALSEAL<sup>TM</sup>-S, 54 mg triethanolamine (TEOA), 80 mg monopotassium phosphate (KPhos) (1.2% by weight or 19 mM), 40 mg vinylcaprolactam (VC) (0.5% by weight), and 0.4 mg of Eosin-Y (10-100 ppm, preferably 30-60 ppm). Surfactant is preferably added, such as PLURONIC<sup>TM</sup> F127, to 0-1% by weight, most preferably 0.25% by weight.  
30 t-Butylperoxide is then added to a concentration of typically 0.0125% by weight. Ferrous gluconate (Fe-Gluconate) may also be added.

**Example 1. Preparation of Amiodarone-loaded FOCALSEAL-L™ Hydrogel Patches Directly onto Tissue for Release of CORDARONE™.**

CORDARONE™ (Wyeth Laboratories Inc., Philadelphia, PA) (0.5 g) was added to FOCALSEAL-L™ macromer solution (Genzyme Corporation, Cambridge, MA) (4.5 mL) and the combination was mixed with a spatula until homogeneous. Over time, the material showed phase separation, which resulted from the precipitation of amiodarone from the macromer solution, and the material formed a submicron amiodarone suspension.

The resulting amiodarone suspension was applied to the myocardium of a live pig by brushing the FOCALSEAL-L™ primer solution onto the myocardium, mixing a small volume of the FOCALSEAL-L™ macromer component containing amiodarone with the primer, and overlaying the mixture with a larger volume of macromer component containing amiodarone. The material was then illuminated with 40 seconds of visible light to polymerize the macromer and form a hydrogel patch onto the tissue. The preparation and use of the FOCALSEAL-L™ hydrogel is described in more detail in the Instructions for Use and in U.S. Patent No. 6,121,341 to Sawhney et al.

The adherence of the hydrogel patch was scored 20 minutes following administration to the heart. The method of adherence scoring is detailed in Table 1 below. The scale ranges from 0 to 4, with the numbers at the lower end of the scale indicating that the gel was more easily removed, and the numbers at the higher end of the scale indicating that more force was needed to remove the hydrogel patch. The hydrogel patches showed good adherence on the porcine myocardium, with adherence scores ranging between 3 to 4.

**Table 1: Adherence Scoring For Gel Patches On Tissue**

<b>Adherence Score</b>	<b>Decision Criteria</b>
0	Gel patch falls off when touched or has fallen off during test.
1	The entire piece of gel patch can be removed by lifting one end of the gel patch.
2	Peeling motion is required to remove the gel patch.
3	Scraping is required to remove the gel patch.
4	Vigorous, repeated scraping is required to remove the gel patch. Gel patch can only be removed in pieces.

**Example 2. Amiodarone in a Solid Particulate Form in FOCALSEAL-L™.**

5           Amiodarone (Isochem, SNPE North America, Princeton, NJ) (11 g) was added to a solution of distilled water containing 0.3125% PLURONIC™ F127 as surfactant (600 g). The particles were mixed to form a coarse suspension using a Caframo overhead mixer at 500 rpm for 5 minutes. Once the particles were completely wetted with the aqueous surfactant solution,

10          the mixture was transferred to a microfluidizer (Microfluidics International Corp., Newton, MA) and homogenized at 20,000 psi for 15 minutes.

The fine suspension was transferred to a 2 L flask and assayed for drug content by HPLC. Based on the assay results, the drug concentration was adjusted to 1.43% by adding a solution of 0.25% PLURONIC™ F127 in

15          distilled water. The solution was mixed well and part of the solution (700 g) was transferred to a 2 L beaker. The FOCALSEAL-L™ macromer (200 g) was added to the beaker and mixed until dissolved. A buffer containing 10X the buffer formulation components was added to the solution (95 g) and mixed for 30 minutes. Vinyl caprolactam (5 g) was added to the solution and

20          mixed for an additional 30 minutes. The resulting suspension of amiodarone in FOCALSEAL-L™ macromer was transferred into syringes and frozen at -40°C prior to use.

An adherence testing scheme that is similar to the one described in Example 1 was performed.

The solid particulate form in FOCALSEAL-L™ gels received adherence scores that were similar to the adherence scores of the  
5 CORDARONE™-loaded macromer formulation.

**Example 3. Release rate of Amiodarone from Hydrogels.**

Three different particle sizes of amiodarone were tested to determine the effect of particle size on release rate from hydrogels. Amiodarone was obtained from three different suppliers. Amiodarone purchased from a first  
10 supplier (Sigma) was determined to have a mean particle size of 25 microns by particle size analysis using a Malvern Mastersizer 2000. Amiodarone from a second supplier (Isochem) had a particle size of 19 microns. A third particle size was obtained by mixing CORDARONE™ brand amiodarone with a hydrogel forming solution, as described in Example 1. The  
15 CORDARONE™ material is an injectable solution of amiodarone in water containing TWEEN™ surfactant and benzyl alcohol. Upon mixing with the gel-forming solution, the amiodarone precipitated, forming a hazy suspension of non-settling particles. Microscopic examination indicated that these particles were submicron in size. Amiodarone from the other two  
20 suppliers was prepared in gels according to the procedure described in Example 2. The gel forming solution for all three types of amiodarone was FOCALSEAL-L™ macromer.

After mixing amiodarone into the gel forming solutions, gel patches in the shape of disks were formed by polymerizing 0.5 mL of the formulation  
25 in a 1 cm diameter TEFLON™ fluorocarbon mold with visible light. Gel disks were placed in a flow-through dissolution apparatus and sampled over time. Drug release kinetics were determined by measuring the residual drug in the gel disks as a function of time.

The elution curves of amiodarone are shown in Figure 1. It can be  
30 seen that the efflux of amiodarone was slowest from the larger solid particles (i.e. Sigma particles of 25 microns), faster from the smaller solid particles (i.e. Isochem Particles of 19 microns), and fastest from the submicron

precipitate (i.e. CORDARONE™ particles of less than 1 micron). Thus, even neglecting the possible influence of the excipients introduced with the CORDARONE™ preparation, the efflux rate of the poorly soluble amiodarone is controllable by selection of the particle size. Moreover, appropriate efflux rates for cardiac tissue treatment may be obtained by this means.

**Example 4: Effect of CORDARONE™ Addition on Modulus and pH of FOCALSEAL-L™ Patches**

This study was to evaluate the change in gel patch stiffness and formulation pH following dilution of the hydrogel with 0 to 20% (w/w) CORDARONE™ (0 to 20% weight amiodarone/weight of hydrogel). This formulation would have the advantage of using off-the-shelf commercial products and allow operating room mix-in.

FOCALSEAL-L™ was prepared by adding known volumes of FOCALSEAL-L™ to CORDARONE™ to achieve 0 to 20% CORDARONE™ loading.

The graph shown in Figure 2A demonstrates a decrease in pH and modulus as CORDARONE concentration is increased. CORDARONE can be loaded into the FOCALSEAL-L formulation at levels up to 15% and maintain acceptable pH and modulus values.

**Example 5: Effect of Amiodarone (Particulate Form) Addition on Modulus and pH of FOCALSEAL-L™**

This experiment was conducted to evaluate the change in gel stiffness and formulation pH following addition of 0 to 10% amiodarone particles to the macromer solution which was then polymerized to form hydrogel. This formulation would be prepared as a suspension of amiodarone particles in a frozen FOCALSEAL-L™ syringe.

FOCALSEAL-L™ was prepared by dispersing known amounts of amiodarone (particulate form) in a surfactant solution, then adding the appropriate FOCALSEAL formulation components that resulted in final amiodarone concentrations between 0 and 10%. The solution was mixed for 3 hours prior to pH and modulus measurements.

The graph shown in Figure 2B demonstrates a decrease in pH and modulus as amiodarone concentration (particulate form) is increased. Amiodarone can be loaded into the FOCALSEAL-L™ formulation at levels to about 1.5% and maintain acceptable pH and modulus values.

5     **Example 6: Adherence Testing of *In Vitro* Polymerized FOCALSEAL-L™ Hydrogels Patches Using the Pig Lung Inflation Model.**

This experiment was conducted to evaluate over 24 hour the adherence of FOCALSEAL-L™ hydrogel patches prepared by applying a preformed hydrogel polymerized *in vitro* in the shape of a disk onto an inflating, explanted pig lung.

10     FOCALSEAL-L™ hydrogel disks were prepared by placing 0.5 mL of macromer solution into a convex mold and illuminating the macromer from between 10 to 40 seconds. To apply the disks to the pig lung, the lung was brushed with FOCALSEAL™ primer and a drop of FOCALSEAL™  
15     macromer was applied to the underside of the disk. The disk was then placed on the primed tissue and then crosslinked by iron-redox and photopolymerization chemistries. The lung was attached to an inflation/deflation apparatus for 24 hours. The disks were then evaluated for their relative tissue adherence using the Adherence Scoring Scale detailed in  
20     Example 1.

**Example 7: Evaluation of FOCALSEAL-S® Macromer with Amiodarone (1% and 4%) on Porcine Cardiac Tissue.**

This study was conducted to evaluate and measure after 7 days the amount of amiodarone delivered from the hydrogel patches into cardiac  
25     tissue using FOCALSEAL-S® macromer solutions (obtained from Genzyme) loaded with 1% and 4% amiodarone deposited and polymerized *in vivo* on a beating porcine heart.

Treatment Schedule:

<i>Group</i>	<i>Carrier</i>	<i>Drug loading</i>	<i>Sites per Pig</i>
Group 1	FOCALSEAL-S® macromer	Control 0%	2
Group 2	FOCALSEAL-S® macromer	1% amiodarone	2
5 Group 3	FOCALSEAL-S® macromer	4% amiodarone	2

Table 2 shows the individual and average volumes of macromer solution applied to pig atria and ventricles. The volumes of drug loaded macromer solution were  $0.5 \pm 0.1$  mL.

10 **Table 2. Macromer Solution Volumes Applied to Pig Atria and Ventricles**

<i>PIG #</i>	<i>MACROMER SOLUTION</i>	<i>ATRIUM (ML)</i>	<i>VENTRICLE (ML)</i>
1	CONTROL (GEL ONLY)	0.6	0.4
	1% AMIODARONE	0.6	0.4
	4% AMIODARONE	0.5	0.6
	Average $\pm$ SD	$0.6 \pm 0.1$	$0.5 \pm 0.1$
2	CONTROL (GEL ONLY)	0.5	0.5
	1% AMIODARONE	0.6	0.4
	4% AMIODARONE	0.6	0.6
	Average $\pm$ SD	$0.6 \pm 0.1$	$0.5 \pm 0.1$

Hydrogel Drug Extraction Results:

15 Table 3 shows the individual amounts of amiodarone released from 1% and 4% amiodarone-loaded gels, respectively. The 1% and 4% amiodarone-loaded gel patches released on average  $39 \pm 9\%$  and  $19 \pm 3\%$  of the drug, respectively.

**Table 3. Amiodarone Released from 1% and 4% Drug-loaded FOCALSEAL-S® Gels**

<i>PIG #</i>	<i>SAMPLE</i>	<i>% AMIODARONE RELEASED</i>
1	1% Atrium gel	35.6
	4% Atrium gel	20.6
	1% Ventricle gel	26.8
	4% Ventricle gel	18.5
2	1% Atrium gel	36.6
	4% Atrium gel	23.6
	1% Ventricle gel	53.3
	4% Ventricle gel	20.1

Tissue Analysis - Drug Content:

Table 4 and Figure 4 show the tissue levels of amiodarone following delivery for seven days from 1% and 4% loaded FOCALSEAL-S® hydrogel patches.

Atrial tissue under 1% and 4% gels had average amiodarone concentrations of  $84 \pm 35$   $\mu\text{g/g}$  tissue and  $155 \pm 73$   $\mu\text{g/g}$  tissue, respectively. Ventricle tissue under 1% and 4% gel patches showed average amiodarone concentrations of  $24 \pm 3$   $\mu\text{g/g}$  tissue and  $78 \pm 13$   $\mu\text{g/g}$  tissue, respectively.

Lung tissue adjacent to gel-treated sites showed amiodarone levels not exceeding 17  $\mu\text{g/g}$  tissue.

**Table 4. Amiodarone Tissue Concentrations under Control and Drug loaded FOCALSEAL-S**

<i>Tissue Sample</i>	<i>[Amiodarone] (<math>\mu\text{g/g}</math> tissue)</i>	
	<i>Pig # 1</i>	<i>Pig # 2</i>
Rt. Atrium - control gel	$0 \pm 0$	$0 \pm 0$
Rt. Atrium - 1% gel	$92 \pm 42$	$75 \pm 33$
Rt. Atrium - 4% gel	$162 \pm 89$	$147 \pm 73$
Rt. Ventricle - control gel	$0 \pm 0$	$0 \pm 0$
Rt. Ventricle - 1% gel	$24 \pm 3$	N.A.
Rt. Ventricle - 4% gel	$86 \pm 6$	$70 \pm 14$

N.A. = sample not available.

These results demonstrate that FOCALSEAL-S delivers therapeutically-relevant levels ( $\geq 20$   $\mu\text{g/g}$  tissue) of amiodarone to pig myocardium over 7 days. Atrial tissue under 1% and 4%-amiodarone-loaded gels contained 84 and 155  $\mu\text{g/g}$  tissue, respectively. Ventricle myocardium under 1% and 4% gels showed 24 and 78  $\mu\text{g/g}$  tissue, respectively. While adjacent lung samples showed the presence of amiodarone, levels were much lower than those found in coated cardiac tissue.



**Example 8: Evaluation of FOCALSEAL-M® with Amiodarone and FOCALSEAL-S® with Amiodarone on Canine Cardiac Tissue**

This study was designed to evaluate the adherence of FOCALSEAL-M® and FOCALSEAL-S® macromer solutions with and without  
 5 amiodarone on a canine heart. Drug loaded FOCALSEAL-S® or FOCALSEAL-M® macromer solutions were applied on the right atrium in 8 dogs (N = 4 dogs/group) then photopolymerized *in situ*. All dogs received both control (0%) and 0.5% amiodarone-loaded hydrogel.

Hydrogel Adherence at 7 days

10 Gel adherence was scored using a 5-point scale as discussed above. Individual and average adherence scores for hydrogels are listed in Tables 5, respectively.

On the 0 to 4 adherence scale described above, control hydrogels (no drug) received an average score of 3.4 and amiodarone-loaded hydrogels  
 15 received an average score of 3.6. Hydrogels formed using FOCALSEAL-S® and FOCALSEAL-M® macromer solutions showed equivalent adherence.

**Table 5. Average Adherence Scores  $\pm$  S.D.**

MACROMER TYPE	CONTROL	TREATMENT
FOCALSEAL-S	3.5 $\pm$ 0.0	3.6 $\pm$ 0.5
FOCALSEAL-M	3.4 $\pm$ 0.3	3.6 $\pm$ 0.3

Drug Analysis:

20 FOCALSEALFOCALSEALThe data show 31  $\pm$  8% amiodarone was released after 7 days *in vivo* implantation from hydrogel patches prepared with the FOCALSEAL-S<sup>TM</sup> and 37  $\pm$  10% was released from gel patches prepared with the FOCALSEAL-M<sup>TM</sup> macromer solutions.

This study determined the amiodarone concentrations in each dog's  
 25 right atrial tissue under the drug-loaded hydrogels in the FOCALSEAL-S and FOCALSEAL-M treatment groups. Tissue under the FOCALSEAL-S drug-loaded hydrogel showed an average amiodarone concentration of 84  $\pm$  81  $\mu$ g/g tissue; tissue under the FOCALSEAL-M hydrogel showed an average amiodarone concentration of 34  $\pm$  17  $\mu$ g/g tissue. Analysis of the  
 30 myocardial tissue under the control hydrogel and untreated area showed no

detectable drug levels in any of the animals. In addition, no drug was detected in any of the distal cardiac or lung tissue samples.

**Example 9: Effect of FOCALSEAL-S<sup>TM</sup> + Amiodarone (0.5% and 1%) on Dog Cardiac Tissue.**

5 A dog study was conducted as described in Example 8. Table 6 shows the average amiodarone concentrations in right atrial tissue beneath 0.5% and 1% amiodarone-loaded FOCALSEAL-S<sup>TM</sup>.

The two 0.5% amiodarone-treated dogs showed an average amiodarone concentration of  $94 \pm 24$   $\mu$ M. This result agrees well with the results observed in the study presented in Example 8. The cardiac tissues in two dogs treated with 1% amiodarone-loaded hydrogel had an average amiodarone concentration of  $337 \pm 36$   $\mu$ M.

**Table 6: Amiodarone Concentrations in Dog Atrium**

DOG #	GEL TREATMENT	[AMIODARONE] IN RIGHT ATRIUM ( $\mu$ M $\pm$ SD)
1	0.5% amiodarone	$95 \pm 34$
2		$93 \pm 16$
3	1% amiodarone	$343 \pm 23$
4		$331 \pm 51$

15 None of the other tissue harvested (including right atrial appendage, right ventricle, left atrial appendage, left atrial free wall, left ventricle and distal lung) showed a detectable level of amiodarone in the tissue.

This study confirms the local delivery of the drug amiodarone at therapeutically relevant levels to the the right atrium of the canine heart using hydrogels polymerized from FOCALSEAL macromer solutions. The amount of drug delivered could be increased or decreased by increasing the initial loading of amiodarone into the macromer solutions. Detectable and therapeutically relevant drug levels were confirmed in the cardiac tissue at the site of application of the hydrogels.

**Example 10: Study of Electrophysiology Of Amiodarone-Loaded Hydrogels On The Canine Heart**

This study was designed to evaluate over time the effects on the atrial effective refractory period (AERP) of amiodarone-loaded hydrogels prepared

from FOCALSEAL<sup>TM</sup> macromer solutions applied to the right atrium of canine heart tissue and photopolymerized. Hydrogels were evaluated for their electrophysiological effects at various time points (3-5 days, 10-15 days, and 3 weeks) at the following concentrations of amiodarone: 0% (control), 0.5% and 1%.

This study was conducted using 13 mongrel dogs weighing between 17-30 Kg. Under fluoroscopic guidance, using quadripolar catheters, drug-loaded hydrogel patches were deposited and photopolymerized following application of a priming solution as described earlier on the right atrium, the right ventricle and coronary sinus. Electrophysiological measurements were performed prior to thoracotomy and following thoracotomy closure at the time intervals set out above.

Table 7 show the changes (in %) in AERP of the canine heart tissue below the hydrogels within the control group and within the treated group (0.5% and 1% results combined).

**Table 7: % Changes In AERP As A Function Of Time In Control And Treated Dogs**

Gel Patches (# dogs)	Pre-operative	Day 3-5	Day 10-14	3-6 Weeks
Control (5)	0.2	23.5	4.5	-10.6
Drug loaded (8)	6.4	37	23.6	30.9

In summary, this study shows that the amiodarone-loaded patches on the atrium increases the effective refractory period of the atrium as compared to the control hydrogels free of the drug.

**Example 11: Inclusion of Hyaluronic Acid to increase viscosity of *In Vivo* Polymerized Macromer for delivery of Drug.**

50 mg of 150 kDa sodium hyaluronate (HA) was added to a 10 g aqueous formulation consisting of 1 g FOCALSEAL<sup>TM</sup>-S, 54 mg TEOA, 80 mg KPhos, 40 mg VC, and 0.4 mg of Eosin-Y to make a solution containing

1% HA. 2%, 3%, 4% and 5% HA FOCALSEAL<sup>TM</sup>-S were similarly prepared.

HA is added to modify the viscosities of the FOCALSEAL<sup>TM</sup>-S solutions so that it remains at the site of application on the tissue where it is to be polymerized to form the hydrogel. As shown by Figure 5A, the viscosities of the formulations with HA were significantly higher than the corresponding macromer formulations without the added HA. The moduli and pH of the solutions are shown by Figure 5B.

These solution can then be applied to tissue and polymerized. For example, a first aqueous 5.028 g formulation prepared containing 0.9005 g FOCALSEAL<sup>TM</sup>, 0.0302 g HA, 0.03 g ferrous gluconate (Fe-Gluconate), and 25  $\mu$ L VC, and a second aqueous 5.028 g formulation is prepared containing 0.9005 g FOCALSEAL<sup>TM</sup>, 0.0302 g HA, 126.3 ppm t- Butylperoxide, and 25  $\mu$ L VC, loaded into separate syringes, and placed in a dual syringe holder. A device containing a 1 inch-long static mixer is attached to the end of the syringes. When the aqueous solutions are released from the syringes in a 1:1 ratio, the mixture gels almost instantaneously.

The polymerized hydrogels were tested for adherence in the explanted pig lung inflation model. Two formulations were tested: 5% FOCALSEAL-S<sup>TM</sup> containing 5% by weight HA, and 7% FOCALSEAL-S<sup>TM</sup> containing 3% by weight HA, each with either 0.5% or 1% by weight amiodarone. The adherence score at 40 hrs for the first composition was 3 and for the second composition 3.5.

It is understood that the disclosed methods and compositions are not limited to the particular methodology, protocols, and reagents described as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

We claim:

1. A composition comprising a tissue adherent hydrogel comprising an anti-arrhythmic agent for local delivery to a patient in need thereof.
2. The composition of claim 1 wherein the hydrogel is formed by polymerization of biocompatible, biodegradable, synthetic, water soluble and covalently reactive macromers.
3. The composition of claim 1 wherein the anti-arrhythmic agent is selected from the group consisting of sodium channel blockers, beta-adrenergic blockers, repolarization prolonging agents, and calcium channel blockers.
4. The composition of claim 3 wherein the anti-arrhythmic agent is selected from the group consisting of lidocaine, moricizine, mexiletine, tocainide, procainamide, encainide, flecainide, tocainide, phenytoin, propafenone, quinidine, disopyramide, flecainide, propranolol, esmolol, amiodarone, artilide, bretylium, clofilium, isobutilide, sotalol, azimilide, dofetilide, dronedarone, ersentilide, ibutilide, tedisamil, trecetilide, verapamil, diltiazem, digitalis, adenosine, nickel chloride, and magnesium.
5. The composition of claim 3 wherein the anti-arrhythmic agent is a repolarization prolonging agent.
6. The composition of claim 5 wherein the anti-arrhythmic agent is selected from the group consisting of amiodarone, sotalol and dronedarone.
7. The composition of claim 6 wherein the anti-arrhythmic agent is amiodarone.
8. The composition of claim 1 wherein the anti-arrhythmic agent is present in a dosage which is sufficient to produce a therapeutically effective level of the agent in the cardiac tissue for at least four days after implantation.
9. The composition of claim 1 wherein the anti-arrhythmic agent is poorly soluble in water.
10. The composition of claim 1 wherein the anti-arrhythmic agent is in nanoparticulate form precipitated within the hydrogel.
11. The composition of claim 1 wherein the anti-arrhythmic agent is encapsulated in a biodegradable material and suspended in the hydrogel.

12. The composition of claim 1 wherein the hydrogel is polymerized *in vitro* with the drug to form a hydrogel patch, prior to administration to a tissue.

13. The composition of claim 1 comprising a diacrylated polyethylene oxide comprising biodegradable linkages selected from the group consisting of monomers and oligomers of carbonates and hydroxyacids, polymerized to form a hydrogel degrading in a period following application to tissue which minimizes tissue inflammation or fibrosis, and amiodarone in a dosage effective to lengthen atrial effective refractory period.

14. The composition of claim 1 in a kit further comprising means for increasing adhesion of the hydrogel to tissue.

15. The composition of claim 14 wherein the means for increasing adhesion is biocompatible, biodegradable, synthetic, water soluble and covalently reactive macromers polymerizable to form an adhesive between the hydrogel and tissue.

16. The composition of claim 1 further comprising a viscosity modifying agent.

17. The composition of claim 16 wherein the viscosity modifying agent is selected from the group consisting of glycosaminoglycans, carboxymethyl cellulose, dextran, dextran sulfate, and polyvinylpyrrolidone.

18. A solution comprising biocompatible, biodegradable, synthetic, water soluble and covalently reactive macromers polymerizable to form a tissue adhesive hydrogel degrading in a period of less than one month after application to the tissue and an anti-arrhythmic agent in a dosage effective to lengthen atrial effective refractory period.

19. The solution of claim 18 comprising a diacrylated polyethylene oxide comprising biodegradable linkages degrading in a period of less than about two weeks following application to the tissue.

20. The solution of claim 19 wherein the biodegradable linkages are selected from the group consisting of carbonate monomers and hydroxy acids.

21. The solution of claim 18 wherein the anti-arrhythmic agent is selected from the group consisting of lidocaine, moricizine, mexiletine, tocainide, procainamide, encainide, flecanide, tocainide, phenytoin, propafenone, quinidine, disopyramide, flecainide, propranolol, esmolol, amiodarone, artilide, bretylium, clofilium, isobutilide, sotalol, azimilide, dofetilide, dronedarone, ersentilide, ibutilide, tedisamil, trecetilide, verapamil, diltiazem, digitalis, adenosine, nickel chloride, and magnesium.

22. The solution of claim 18 wherein the anti-arrhythmic agent is selected from the group consisting of amiodarone, sotalol and dronedarone.

23. The solution of claim 22 comprising macromers comprising a diacrylated polyethylene oxide comprising biodegradable linkages selected from the group consisting of monomers and oligomers of carbonates and hydroxyacids, polymerizable to form a hydrogel degrading in a period following application to tissue which minimizes tissue inflammation or fibrosis, and amiodarone in a dosage effective to lengthen atrial effective refractory period.

24. The solution of claim 18 in a kit further comprising reagents for priming the surface of the tissue to which the solution is to be applied, wherein the priming increases the adhesion of the hydrogel to the tissue.

25. The solution of claim 18 further comprising a viscosity modifying agent.

26. The solution of claim 25 wherein the viscosity modifying agent is selected from the group consisting of glycosaminoglycans, carboxymethyl cellulose, dextran, dextran sulfate, and polyvinylpyrrolidone.

27. A method for delivering an anti-arrhythmic agent, comprising topically applying to the surface of cardiac tissue or blood vessels an anti-arrhythmic agent in a hydrogel, or a solution forming a hydrogel.

28. The method of claim 27 comprising administering to the surface of cardiac tissue or blood vessels a solution of biocompatible, biodegradable, synthetic, water soluble and covalently reactive macromers comprising the anti-arrhythmic agent, and polymerizing the macromer solution to form a tissue adherent hydrogel.

29. The method of claim 27 comprising administering to the surface of cardiac tissue or blood vessels a hydrogel formed of biocompatible, biodegradable, synthetic, water soluble and covalently reactive macromers comprising the anti-arrhythmic agent to be delivered.

30. The method of claim 27 wherein the anti-arrhythmic agent is selected from the group consisting of sodium channel blockers, beta-adrenergic blockers, repolarization prolonging agents, and calcium channel blockers.

31. The method of claim 30 wherein the anti-arrhythmic agent is selected from the group consisting of lidocaine, moricizine, mexiletine, tocainide, procainamide, encainide, flecanide, tocainide, phenytoin, propafenone, quinidine, disopyramide, flecainide, propranolol, esmolol, amiodarone, artilide, bretylium, clofilium, isobutilide, sotalol, azimilide, dofetilide, dronedarone, ersentilide, ibutilide, tedisamil, trecetilide, verapamil, diltiazem, digitalis, adenosine, nickel chloride, and magnesium.

32. The method of claim 30 wherein the anti-arrhythmic agent is a repolarization prolonging agent.

33. The method of claim 32 wherein the anti-arrhythmic agent is selected from the group consisting of amiodarone, sotalol and dronedarone.

34. The method of claim 33 wherein the anti-arrhythmic agent is amiodarone.

35. The method of claim 34 wherein the hydrogel comprises a diacrylated polyethylene oxide comprising biodegradable linkages selected from the group consisting of monomers and oligomers of carbonates and hydroxyacids, polymerized to form a hydrogel degrading in a period following application to tissue which minimizes tissue inflammation or fibrosis, and amiodarone in a dosage effective to lengthen atrial effective refractory period.

36. The method of claim 27 further comprising applying to the tissue means for increasing adhesion of the hydrogel to tissue.

37. The method of claim 36 wherein the means for increasing adhesion is biocompatible, biodegradable, synthetic, water soluble and covalently reactive macromers polymerizable to form an adhesive between the hydrogel and tissue.



38. The method of claim 27 wherein the anti-arrhythmic agent is present in a dosage effective to lengthen atrial effective refractory period.

39. The method of claim 27 in which the therapeutically effective level is maintained for at least four days after implantation.

40. The method of claim 27 wherein the hydrogel degrades over a period of time of two weeks or less.

41. The method of claim 27 further comprising administering a viscosity modifying agent in the solution forming the hydrogel.

42. The method of claim 41 wherein the viscosity modifying agent is selected from the group consisting of glycosaminoglycans, carboxymethyl cellulose, dextran, dextran sulfate, and polyvinylpyrrolidone.




Fig. 1

### Effect of Cordarone Loading on Modulus and pH of FS-L




FIG. 2A

### Effect of Amiodarone Loading on Modulus and pH of FS-L




FIG. 2B

# ADHERENCE TESTING OF PRE-FORMED GELS 24 HR PIG LUNG INFLATION MODEL




FIG. 3

Average Amiodarone concentrations in tissue following  
7 day delivery from 1% and 4% loaded gels




FIG. 4

## Viscosity vs HA





FIG 5A

# Modulus & pH



Percentage of Amiodarone

FIG 5B

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 July 2002 (04.07.2002)

PCT

(10) International Publication Number  
**WO 02/051383 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 31/343**,  
A61P 9/06, A61L 24/04, A61K 9/00, 47/34

(74) Agent: **BLUNDELL, Isabelle**; Genzyme Corporation,  
Legal Department, One Kendall Square, Cambridge, MA  
02139 (US).

(21) International Application Number: PCT/US01/49617

(22) International Filing Date:  
27 December 2001 (27.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/258,369 27 December 2000 (27.12.2000) US

(71) Applicants: **GENZYME CORPORATION** [US/US];  
One Kendall Square, Cambridge, MA 02139 (US). **FO-  
CAL, INC.** [US/US]; 4 Maguire Road, Lexington, MA  
02421-3112 (US).

(72) Inventors: **PHILBROOK, Michael, C.**; 365 Marlbor-  
ough Street #6, Boston, MA 02115 (US). **BURNS, James,  
W.**; 182 Standish Road, Watertown, MA 02172 (US).  
**SKINNER, Kevin, C.**; 8 Midland Circle, Andover, MA  
01810 (US). **MILLER, Robert, J.**; 59 Fairway Drive,  
Halifax, MA 02338 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).

**Published:**

— with international search report

(88) Date of publication of the international search report:  
6 March 2003

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: CONTROLLED RELEASE OF ANTI-ARRHYTHMIC AGENTS FROM A BIODEGRADABLE POLYETHYLENE  
OXIDE HYDROGEL FOR LOCAL APPLICATION TO THE HEART

(57) Abstract: Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti-arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed *in vitro* or *in vivo*. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.

WO 02/051383 A3

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/01/49617

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/343 A61P9/06 A61L24/04 A61K9/00 A61K47/34

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Data, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 387 419 A (LEVY ROBERT J ET AL) 7 February 1995 (1995-02-07) cited in the application	1-4, 8-10,12, 16,18, 21,25, 27, 29-31, 36,37, 40,41
Y	example 11 column 3, line 30-33; column 6, line 11-19 and 34-48	1-42
Y	US 5 900 245 A (RUDOWSKY RONALD S ET AL) 4 May 1999 (1999-05-04) cited in the application column 2, line 57-67; column 12, line 23	1-42
	--- -/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

8 July 2002

Date of mailing of the international search report

17/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Borst, M



# INTERNATIONAL SEARCH REPORT

International Application No

PC 01/49617

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 02 16442 A (PURDUE RESEARCH FOUNDATION) 28 February 2002 (2002-02-28)</p> <p>page 4, line 6-14 -----</p>	<p>1-4, 8-10, 12, 16, 18, 19, 21, 25</p>

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 01/49617

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 27-42 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition (Rule 39.1(iv) PCT).
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

International Application No

PC 01/49617

on patent family members

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5387419	A	07-02-1995	NONE	
US 5900245	A	04-05-1999	AU 728281 B2 AU 4587097 A BR 9711537 A EP 0927214 A1 JP 2002514235 T WO 9812243 A1 US 6051248 A US 6217894 B1 US 6177095 B1 US 2001000728 A1 US 6083524 A US 9708537 A ZA 709527 B2 AU 5524996 A AU 9607977 A BR 0815177 A2 EP 11502552 T JP 6121341 A US	04-01-2001 14-04-1998 24-08-1999 07-07-1999 14-05-2002 26-03-1998 18-04-2000 17-04-2001 23-01-2001 03-05-2001 04-07-2000 12-05-1998 02-09-1999 08-10-1996 13-01-1998 07-01-1998 02-03-1999 19-09-2000
WO 0216442	A	28-02-2002	AU 8665101 A WO 0216442 A2 US 2002071869 A1	04-03-2002 28-02-2002 13-06-2002

**THIS PAGE BLANK (USPTO)**